<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521153</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-ZJ-SK-2020</org_study_id>
    <nct_id>NCT04521153</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma</brief_title>
  <official_title>Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a&#xD;
      curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years&#xD;
      after surgery. Perioperative treatment with immunotherapy combined with target therapy is&#xD;
      expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety&#xD;
      and tolerability of camrelizumab combined with apatinib mesylate in the perioperative period&#xD;
      of resectable hepatocellular carcinoma. The primary purpose of this study is to evaluate the&#xD;
      rate of subjects with major pathological response and 3-year event-free survival (EFS) of&#xD;
      camrelizumab combined with apatinib mesylate in the perioperative period of hepatocellular&#xD;
      carcinoma (CNLC Ib-IIIa). The secondary research purpose is to evaluate the R0 resection&#xD;
      rate, the rate of subjects with pathological complete response, EFS, overall survival and&#xD;
      disease-free survival of camrelizumab combined with apatinib mesylate in the perioperative&#xD;
      period of resectable hepatocellular carcinoma. The safety and tolerability is also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a&#xD;
      curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years&#xD;
      after surgery. Perioperative treatment with immunotherapy combined with target therapy is&#xD;
      expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety&#xD;
      and tolerability of camrelizumab combined with apatinib mesylate in the perioperative period&#xD;
      of resectable hepatocellular carcinoma. This trial includes subjects with CNLC&#xD;
      Ib/IIa/IIb/IIIa HCC. All eligible subjects will be randomized (1:1) to experimental group or&#xD;
      control group. In the experimental group, patients will be treated with following:&#xD;
      neoadjuvant therapy (camrelizumab and apatinib, 2 cycles), radical surgery, postoperative&#xD;
      TACE treatment, adjuvant therapy (camrelizumab and apatinib, 6 cycles); in the control group,&#xD;
      patients will be treated with following: radical surgery, postoperative TACE treatment. The&#xD;
      primary purpose of this study is to evaluate the rate of subjects with major pathological&#xD;
      response and 3-year event-free survival (EFS) of camrelizumab combined with apatinib mesylate&#xD;
      in the perioperative period of HCC. The secondary research purpose is to evaluate the R0&#xD;
      resection rate, the rate of subjects with pathological complete response, EFS, overall&#xD;
      survival and disease-free survival of camrelizumab combined with apatinib mesylate in the&#xD;
      perioperative period of resectable HCC. The safety and tolerability is also evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year event-free survival (EFS)</measure>
    <time_frame>3-year</time_frame>
    <description>EFS is defined as the time from randomisation to tumor progression, postoperative relaspse or metastasis, or death, which occur first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The rate of subjects of major pathological response (MPR)</measure>
    <time_frame>30-day</time_frame>
    <description>MPR is defined as less than 50% residual tumor after neoadjuvant therapy of camrelizumab and apatinib therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3-year</time_frame>
    <description>OS is defined as the time from randomisation to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3-year</time_frame>
    <description>DFS is defined as the time from surgery to postoperative relaspse or metastasis, or death, which occur first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>3-year</time_frame>
    <description>EFS is defined as the time from randomisation to tumor progression, postoperative relaspse or metastasis, or death, which occur first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>30-day</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toleraty</measure>
    <time_frame>30-day</time_frame>
    <description>The incidence of adverse evetns, severe adverse events; surgery related safety.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Immunotherapy</condition>
  <condition>Molecular Targeted Therapy</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative camrelizumab combined with apatinib mesylate (q2w, 2 cycles) → radical surgery → postoperative TACE treatment → sequential camrelizumab and apatinib mesylate (q3w, at least 6 cycles) (Note: Surgery within 2-4 weeks after the last administration of neoadjuvant therapy, postoperative TACE treatment at least 4 weeks after surgery, and camrelizumab combined with apatinib mesylate within 2 weeks after TACE treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical surgery→postoperative TACE treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab is administered at 200mg, q2w (2cycles) before radical surgery and 200mg, q3w (at least 6 cycles) after radical surgery</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib Mesylate is administered at 250mg, qd (2 cycles) before radical surgery and 250mg, qd (at least 6 cycles) after radical surgery</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE treatment</intervention_name>
    <description>TACE treatment</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical surgery</intervention_name>
    <description>Radical surgery</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteer to participate in this study and sign an informed consent form&#xD;
&#xD;
          2. Age 18~75 years old, no gender limit&#xD;
&#xD;
          3. Hepatocellular carcinoma confirmed by histopathology, cytology or imaging&#xD;
&#xD;
          4. CNLC stage Ib/IIa/IIb/IIIa hepatocellular carcinoma, except for CNLC IIIa&#xD;
             hepatocellular carcinoma combined with main portal vein tumor thrombus&#xD;
&#xD;
          5. Child-Pugh score: A-B grade (≤7 points)&#xD;
&#xD;
          6. ECOG PS score: 0-1 points&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and&#xD;
             fibrolamellar cell carcinoma; have other active malignancies other than HCC within 5&#xD;
             years or at the same time.&#xD;
&#xD;
          2. Currently accompanied by interstitial pneumonia or interstitial lung disease&#xD;
&#xD;
          3. Existence of active autoimmune disease or history of autoimmune disease and may&#xD;
             relapse&#xD;
&#xD;
          4. Patients with active infection, unexplained fever ≥38.5℃ within 1 week before&#xD;
             randomization, or baseline white blood cell count &gt;15*10^9/L&#xD;
&#xD;
          5. Patients with congenital or acquired immune deficiencies (such as HIV-infected&#xD;
             persons)&#xD;
&#xD;
          6. Those who are known to be allergic to any monoclonal antibodies, anti-angiogenesis&#xD;
             targeted drugs or excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhou, Doctor</last_name>
    <phone>008613801914007</phone>
    <email>zhou.jian@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>180 Fenglin Road</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Zhou, professor</last_name>
      <phone>0086-21-64041990</phone>
      <email>zhou.jian@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Zheng Wang, professor</last_name>
      <phone>0086-21-64041990</phone>
      <email>wzdoc@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jian Zhou, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zheng Wang, professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.</citation>
    <PMID>30350310</PMID>
  </reference>
  <reference>
    <citation>Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Erratum in: Lancet. 2020 Jul 4;396(10243):26.</citation>
    <PMID>31248666</PMID>
  </reference>
  <reference>
    <citation>Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP; CONCORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015 Mar 14;385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9. Epub 2014 Nov 26. Erratum in: Lancet. 2015 Mar 14;385(9972):946.</citation>
    <PMID>25467588</PMID>
  </reference>
  <reference>
    <citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.</citation>
    <PMID>25651787</PMID>
  </reference>
  <reference>
    <citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.</citation>
    <PMID>26808342</PMID>
  </reference>
  <reference>
    <citation>Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019 Jul 28;25(28):3704-3721. doi: 10.3748/wjg.v25.i28.3704. Review.</citation>
    <PMID>31391767</PMID>
  </reference>
  <reference>
    <citation>Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000 Sep 2;356(9232):802-7. Erratum in: Lancet 2000 Nov 11;356(9242):1690.</citation>
    <PMID>11022927</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015 Jun;148(7):1383-91.e6. doi: 10.1053/j.gastro.2015.02.055. Epub 2015 Mar 4.</citation>
    <PMID>25747273</PMID>
  </reference>
  <reference>
    <citation>Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF. Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol. 2005 Feb 7;11(5):700-4.</citation>
    <PMID>15655825</PMID>
  </reference>
  <reference>
    <citation>Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.</citation>
    <PMID>15014006</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.</citation>
    <PMID>26361969</PMID>
  </reference>
  <reference>
    <citation>Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res. 2014 May;44(5):523-31. doi: 10.1111/hepr.12159. Epub 2013 Jun 13.</citation>
    <PMID>23672310</PMID>
  </reference>
  <reference>
    <citation>Zhang XP, Chai ZT, Gao YZ, Chen ZH, Wang K, Shi J, Guo WX, Zhou TF, Ding J, Cong WM, Xie D, Lau WY, Cheng SQ. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. HPB (Oxford). 2019 Dec;21(12):1687-1696. doi: 10.1016/j.hpb.2019.04.014. Epub 2019 May 29.</citation>
    <PMID>31153833</PMID>
  </reference>
  <reference>
    <citation>Wang D, Jia W, Wang Z, Wen T, Ding W, Xia F, Zhang L, Wu F, Peng T, Liu B, Zhou C, Zheng Q, Miao X, Peng J, Huang Z, Dou K. Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy. Onco Targets Ther. 2019 Jul 17;12:5779-5791. doi: 10.2147/OTT.S168447. eCollection 2019.</citation>
    <PMID>31410023</PMID>
  </reference>
  <reference>
    <citation>Chen Q, Shu C, Laurence AD, Chen Y, Peng BG, Zhen ZJ, Cai JQ, Ding YT, Li LQ, Zhang YB, Zheng QC, Xu GL, Li B, Zhou WP, Cai SW, Wang XY, Wen H, Peng XY, Zhang XW, Dai CL, Bie P, Xing BC, Fu ZR, Liu LX, Mu Y, Zhang L, Zhang QS, Jiang B, Qian HX, Wang YJ, Liu JF, Qin XH, Li Q, Yin P, Zhang ZW, Chen XP. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018 Nov;67(11):2006-2016. doi: 10.1136/gutjnl-2018-315983. Epub 2018 May 25.</citation>
    <PMID>29802174</PMID>
  </reference>
  <reference>
    <citation>Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571-580. doi: 10.1016/S1470-2045(20)30011-5. Epub 2020 Feb 26.</citation>
    <PMID>32112738</PMID>
  </reference>
  <reference>
    <citation>Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res. 2019 Jan 15;25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484. Epub 2018 Oct 22.</citation>
    <PMID>30348638</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Camrelizumab; apatinib mesylate; hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

